MERIDIAN BIOSCIENCE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-11-07: Form 8-K; Period of report 2019-11-05; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-11-07: Form 8-K; Period of report 2019-11-07; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2019-10-04: Form 8-K; Period of report 2019-10-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2019-08-14: Form 8-K/A; Period of report 2019-06-03; Description 9.01 Financial Statements and Exhibits; Details 9.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-11-07 | 8-K | 2019-11-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 5, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) entered into an Amended and Restated Employment Agreement (the “Agreement”) with Jack Kenny, its Chief Executive Officer. | d829708d8k.htm |
| 2019-11-07 | 8-K | 2019-11-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 7, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the fourth quarter and fiscal year ended September 30, 2019. 7.01 On November 7, 2019, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the earnings release, discuss key elements of its business strategy and discuss other business and financial developments. | d764637d8k.htm |
| 2019-10-04 | 8-K | 2019-10-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 1, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) promoted Bryan T. Baldasare to Chief Financial Officer of the Company effective immediately. | form8k100419.htm |
| 2019-08-14 | 8-K/A | 2019-06-03 | 9.01 Financial Statements and Exhibits | 9.01 On June 3, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) filed a Current Report on Form 8-K (the “Original Filing”) to report completion of the previously announced acquisition of substantially all of the assets of GenePOC Inc., a corporation incorporated under the laws of Canada, pursuant to the Share Purchase Agreement, dated as of April 29, 2019 (the “Purchase Agreement”), by and among Meridian, Meridian Bioscience Canada Inc., a corporation incorporated under the laws of British Columbia and a direct wholly-owned subsidiary of the Company, GenePOC Inc., the shareholders of GenePOC Inc., and Apres-demain Holding SA, solely in the capacity of Shareholders’ Representative (“Shareholders’ Representative”). | d792041d8ka.htm |
| 2019-07-30 | 8-K | 2019-07-30 | 2.02 Results of Operations and Financial Condition | 2.02 On July 30, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the third fiscal quarter ended June 30, 2019. | d784323d8k.htm |
| 2019-06-25 | 8-K | 2019-06-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 21, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) and Eric S. Rasmussen entered into a Separation Agreement and General Release (the “Separation Agreement”) which provides that Mr. Rasmussen’s last day of employment as Meridian’s Executive Vice President and Chief Financial Officer shall be June 28, 2019. | d769673d8k.htm |
| 2019-06-06 | 8-K | 2019-06-06 | 7.01 Regulation FD Disclosure | 7.01 On June 6, 2019, Meridian Bioscience, Inc. (the “Company”) will present at the William Blair Healthcare Conference. | d742327d8k.htm |
| 2019-06-03 | 8-K | 2019-06-03 | 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 2.01 On June 3, 2019, the Acquisition was consummated, and, in accordance with the Purchase Agreement, Buyer purchased substantially all of the assets and assumed certain specified liabilities of Seller by means of a two-step transaction. 2.03 The information contained under Item 2.01 above regarding the Promissory Note is hereby incorporated by reference in its entirety into this Item 2.03. 7.01 On June 3, 2019, the Company issued a press release announcing the completion of the Acquisition. | d738925d8k.htm |
| 2019-05-31 | 8-K | 2019-05-24 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information contained under Item 1.01 above is hereby incorporated by reference in its entirety into this Item 2.03. | d753199d8k.htm |
| 2019-04-30 | 8-K | 2019-04-26 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 On April 30, 2019, Meridian issued a press release announcing results for the second fiscal quarter ended March 31, 2019. 5.02 The information in Item 1.01 is incorporated by reference into this Item 5.02. 8.01 As described above in Item 2.02, on April 30, 2019, the Company issued a press release announcing results for the second fiscal quarter ended March 31, 2019. | d940258d8k.htm |
| 2019-04-30 | 8-K | 2019-04-29 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On April 30, 2019, the Company issued a press release announcing the Purchase Agreement. | d739187d8k.htm |
| 2019-04-02 | 8-K | 2019-04-02 | 2.02 Results of Operations and Financial Condition | 2.02 On April 2, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing preliminary revenue results for the second fiscal quarter ended March 31, 2019 and revised financial guidance for the fiscal year ending September 30, 2019. | form8k040219.htm |
| 2019-01-25 | 8-K | 2019-01-24 | 5.07 Submission of Matters to a Vote of Security Holders | form8k012419.htm | |
| 2019-01-24 | 8-K | 2019-01-24 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 24, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing results for the first quarter ended December 31, 2018. 7.01 On January 24, 2019, Meridian is hosting a conference call for the benefit of its investors to discuss the results set forth in the earnings release. | d569042d8k.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 On January 7, 2019, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release announcing preliminary revenue results for the first fiscal quarter ended December 31, 2018. | form8k010719.htm |